cbdMD to Report Q1 2025 Earnings with EPS Forecast at -0.36 USD

Summary

cbdMD (YCBD) is set to announce its quarterly earnings on May 15, 2025. Analysts predict an EPS of -0.36 USD. As of May 13, the stock price was 1.01 USD, declining 82.75% over the past year, indicating long-term shareholder dissatisfaction ahead of the earnings report. Benzinga

Impact Analysis

1. Business Overview Analysis

• business_model: cbdMD operates primarily in the CBD industry, offering products under brands like cbdMD and paw cbd, as well as functional mushroom brand ATRX Labs. This positions them within the health and wellness sector, focusing on CBD and related products.Press Releases
• market_position: cbdMD is recognized as a leading and trusted CBD company in the U.S. However, the significant drop in stock value suggests challenges in maintaining competitive advantages or market share.Benzinga+ 2
• recent_events_impact: The announcement of the quarterly earnings with a forecasted negative EPS hints at continuing operational challenges. Previous earnings showed a reduction in losses, which might have provided some optimism, but the overall decline in stock price suggests that shareholders are not confident about future performance.Press Releases

2. Financial Statement Analysis

• income_statement: Analysts are predicting continued losses, with EPS at -0.36 USD, reflecting ongoing struggles to achieve profitability. Previous fiscal results showed a reduction in losses, indicating potential initial improvements not sustained.Benzinga
• balance_sheet: Without specific details in the references, it’s challenging to assess asset quality or liability structure. However, the stock price decline may indicate concerns over financial stability and asset management.Benzinga
• cash_flow: There is no explicit information regarding cash flow, but ongoing losses suggest challenges in generating operational cash, potentially affecting investment capabilities and financing activities.Benzinga
• key financial ratios: Without further details, specific ratio calculations are not possible. The negative EPS indicates weak profitability metrics, and the significant stock price devaluation suggests potential liquidity and solvency issues.Benzinga

3. Valuation Assessment

• The current stock price and significant devaluation suggest that the company is facing serious valuation challenges compared to historical averages and industry peers.Benzinga

4. Opportunity Analysis

• Potential opportunities might lie in expanding product lines or improving operational efficiencies, but these are speculative without explicit new strategies or product announcements.Press Releases

5. Risks

• The primary risk highlighted is the ongoing financial loss and decreasing stock value, which could affect investor confidence and the company’s ability to secure financing or investments.Benzinga